Browse the evidence

Cellular senescence drives inflammaging through the secretion of the Senescence-Associated Secretory Phenotype (SASP), which promotes chronic sterile inflammation and age-related pathologies.

Aging is associated with the accumulation of 'zombie' cells (senescent cells) that secrete inflammatory signals (SASP). This chronic inflammation contributes to many age-related diseases. While senolytics (drugs that kill these cells) are being developed, current evidence supports lifestyle factors like physical activity, which improves mitochondrial function and may help manage inflammation.

Mitochondrial dysfunction, specifically the release of mitochondrial DAMPs (mtDAMPs) like oxidized mtDNA and cardiolipin, activates innate immune pathways (NLRP3, cGAS/STING, NF-κB) to drive inflammaging.

Mitochondrial health is crucial for managing inflammation. Impaired mitochondria release signals that trigger chronic inflammation. Physical activity improves mitochondrial function and may help reduce this inflammatory burden.

Bariatric surgery is the most effective treatment for both obesity and T2DM, offering benefits beyond weight loss by recovering islet function and normalizing gut hormones.

For severe obesity and T2DM, bariatric surgery is currently the most effective treatment, working by restoring gut hormones (GLP-1, PYY) and beta-cell function, not just by reducing stomach size. It should be considered when lifestyle changes fail, despite surgical risks.

A bimodal GLP-1/MK-801 conjugate produces synergistic weight loss and metabolic improvements in diet-induced obese rodents by targeting NMDA receptors in GLP-1-expressing brain regions, while mitigating the adverse behavioral and physiological effects of MK-801 monotherapy.

This research describes a new experimental drug that combines two mechanisms to treat obesity in animals. It works by targeting specific brain cells to reduce food intake and increase energy expenditure without the side effects of older drugs. This is not yet available for humans.

Peri-operative protein or amino acid supplementation does not significantly improve muscle strength (quadriceps or handgrip) or functional outcomes in total joint arthroplasty patients.

Do not expect protein supplements to restore your leg strength after surgery. The evidence shows they help keep muscle mass from shrinking, but they do not significantly improve strength or walking ability on their own. You must combine supplementation with physical therapy and exercise to regain strength.

Sibutramine increases the risk of nonfatal cardiovascular events (myocardial infarction and stroke) in patients with pre-existing cardiovascular disease or type 2 diabetes with additional risk factors, leading to its contraindication in these populations.

If you have heart disease, a history of stroke, or diabetes combined with other heart risks (like high blood pressure or smoking), sibutramine is not safe for you. It increases your chance of having a heart attack or stroke. Do not use this medication if you fall into these categories; consult your doctor for safer alternatives.

Higher dietary resistant starch intake is NOT significantly associated with reduced cardiovascular disease (CVD) mortality.

Do not rely on resistant starch alone to protect your heart. This study found no significant link between RS intake and reduced cardiovascular mortality. While RS may offer other benefits, managing overall cardiovascular risk requires a holistic approach including blood pressure, lipid management, and overall diet quality, not just increasing RS.

Traditional weight management strategies, including lifestyle interventions and metabolic and bariatric surgery (MBS), are generally ineffective for reducing hyperphagia in patients with rare MC4R pathway diseases because they do not address the underlying pathophysiology.

For patients with rare genetic obesity (POMC, LEPR, BBS, etc.), standard diets, exercise programs, and even weight-loss surgery often fail to control the insatiable hunger (hyperphagia). This is not a failure of willpower but a failure of the treatment to address the specific brain signaling defect. Recognizing this can reduce caregiver guilt and shift focus toward seeking targeted genetic therapies.

There is no statistically significant association between weight loss (amount or frequency) and cancer mortality in men or women.

Losing weight, whether once or repeatedly, does not appear to reduce your risk of dying from cancer based on this study. Focus on other aspects of health.

Selective activation of Gs signaling in enteroendocrine K cells increases endogenous GIP secretion, which improves glucose tolerance in obese and diabetic mouse models.

This research suggests that therapies targeting the specific signaling pathways (Gs) in gut K cells to boost natural GIP production could be a viable strategy for managing obesity and Type 2 Diabetes, potentially offering better glucose control than current approaches that rely on external hormone administration.

Reducing global obesity prevalence to 2019 levels could save an estimated US$2.2 trillion annually by 2060 through healthcare and productivity-related cost savings.

Addressing obesity at a population level saves massive amounts of money globally. Public health policies that reduce obesity prevalence have a high economic return on investment.

Other GLP-1 receptor agonists and SGLT2 inhibitors, including semaglutide, dulaglutide, and canagliflozin, did not demonstrate a statistically significant elevation in gynecologic tumor risk compared to controls.

If you are taking other GLP-1 receptor agonists (like semaglutide or dulaglutide) or SGLT2 inhibitors (like canagliflozin or empagliflozin), this network meta-analysis did not find a statistically significant increase in gynecologic tumor risk for these agents. However, the authors note that more data is needed to confirm whether the association with tirzepatide is causal.

GLP-1 receptor agonists (GLP-1 RAs) are not cost-effective at current prices, requiring significant price reductions to meet standard willingness-to-pay thresholds.

GLP-1 RAs are clinically effective but not cost-effective at current prices. They should be used selectively (e.g., for those who cannot undergo surgery) and only if pricing aligns with their health benefits.

Peripheral GLP-1 signaling is not essential for long-term energy balance or bodyweight regulation in humans or rodents, as evidenced by normal body weight in GLP-1R knockout mice and lack of effect from peripheral antagonism.

Your body's natural production of GLP-1 in the gut does not significantly control your long-term weight. This is why lifestyle changes alone often fail to sustain weight loss, and why pharmacologic doses that strongly activate brain receptors are needed for significant weight reduction.

Hypothalamic Glp1r-expressing cells are predominantly neuronal and localized to arterial vascular beds, whereas Gipr-expressing cells are predominantly non-neuronal (oligodendrocytes and pericytes) and localized to venous vascular beds.

This research suggests that GLP-1 and GIP drugs work through different pathways in the brain. GLP-1 primarily targets neurons and arterial blood vessels, while GIP targets support cells (oligodendrocytes) and venous blood vessels. This distinct localization may explain why combining them (dual agonism) is more effective for weight loss than using GLP-1 alone.

High-calorie diets uncouple hypothalamic oxytocin (PVNOT) neurons from gut-derived CCK signaling via increased kappa-opioid tone and reduced CCKAR expression, rendering CCK ineffective at suppressing food intake.

If you are eating a high-calorie, high-fat/sugar diet, your body's natural ability to feel full from gut hormones like CCK is biologically suppressed. This is not a failure of willpower but a broken signal. To regain control, you must address the diet composition to potentially restore this pathway, or utilize interventions (like specific pharmacological combinations of OT and CCKAR agonists shown in the study) that bypass this block.

Selective activation of oxytocin-expressing PVN neurons (PVNOT) restores the ability of cholecystokinin (CCK) to suppress food intake in diet-induced obese mice.

This finding suggests that simply taking CCK might not work for obese individuals because their oxytocin pathway is disconnected. Future therapies might need to combine CCK with agents that activate oxytocin neurons or bypass this block to be effective.

GLP-1 receptor internalization is arrestin-independent and relies on a dual mechanism involving Gs/Gi/o protein activation, GRK phosphorylation, and both clathrin- and caveolae-mediated endocytosis.

This research clarifies that GLP-1 drugs work by engaging specific cellular recycling pathways (clathrin and caveolae) rather than the arrestin pathway. This mechanistic insight aids in designing drugs with optimized duration and fewer side effects, though it does not change immediate patient behavior.

Standardized Environmental, Social, and Governance (ESG) metrics for nutrition and health in the food and beverage sector are currently available but exhibit substantial heterogeneity in quality, domain coverage, and strength, limiting their ability to drive scalable public health impact.

For investors and policymakers, the current landscape of ESG nutrition metrics is fragmented. To drive real health outcomes, stakeholders must prioritize frameworks that use standardized, quantitative definitions of product healthfulness (e.g., using Nutrient Profiling Systems) and ensure equitable distribution of healthy foods. Simply having an ESG policy is insufficient; the metrics must be rigorous, verifiable, and aligned with scientific dietary guidelines.

Public awareness of the clinical success of anti-obesity medications (AOMs) does not reduce obesity stigma or shift public perception of obesity from a failure of willpower to a biological medical condition.

Health communicators and policymakers should not assume that highlighting the success of GLP-1 medications will automatically reduce obesity stigma. Since stigma is robustly linked to personal weight loss experiences and willpower beliefs, interventions must directly address these cognitive biases rather than relying on medical awareness alone.

Intensive lifestyle intervention (diet and exercise) does not significantly alter the rate of kidney function decline (eGFR slope) over 10 years in patients with type 2 diabetes and preserved baseline kidney function compared to usual care.

If you have type 2 diabetes and normal kidney function, an intensive lifestyle program focusing on weight loss and 175 minutes of weekly exercise will not significantly change the *rate* at which your kidney function declines over 10 years compared to standard diabetes care. However, it may help maintain a slightly higher average kidney function level, especially if your baseline function is already slightly reduced (eGFR <80). Focus on the overall health benefits rather than expecting a specific kidney outcome.

A remote, call-center-directed weight loss intervention combining diet and exercise counseling does not result in significant weight loss or improved cardiovascular risk factors in adult survivors of childhood acute lymphoblastic leukemia (ALL) compared to self-directed weight loss.

Standard remote weight loss programs are unlikely to succeed for adult survivors of childhood leukemia. Success requires tailoring to their specific health history, including managing pain and other treatment side effects, and likely involves more direct clinician involvement rather than purely remote coaching.

Circulating IGF-1 concentrations are not associated with all-cause, cardiovascular disease, or cancer-related mortality risk.

There is no evidence from this study that your natural IGF-1 levels predict your risk of death from cancer, heart disease, or other causes. You do not need to try to manipulate IGF-1 levels for longevity based on this data.

Loss-of-function mutations in the myostatin (MSTN) gene cause excessive skeletal muscle growth (hypertrophy) and increased strength by removing the natural inhibition on muscle development.

This paper describes a rare genetic condition (myostatin deficiency) that causes massive muscle growth. For the average person, this is not a viable or safe intervention. However, understanding that myostatin limits growth suggests that therapies blocking it (under medical supervision) might help those with muscle-wasting diseases, but it is not a recommendation for healthy individuals seeking hypertrophy.